Summary
Abbott Laboratories (ABT) announced an upcoming offering of senior unsecured notes by its indirect wholly-owned Irish subsidiary, Abbott Ireland Financing DAC. These notes will be offered in compliance with Regulation S, meaning they are exempt from registration under the U.S. Securities Act of 1933 and will not be offered or sold to U.S. persons in the United States. Abbott Laboratories will provide an unconditional and irrevocable guarantee for these notes, which are unsecured and unsubordinated. The primary purpose of this debt offering is to fund the redemption and/or repayment of a portion of Abbott's outstanding 2.900% Notes due 2021. This includes covering any associated premium, accrued interest, and other related expenses. This move suggests Abbott is strategically managing its debt profile and potentially refinancing existing debt at what may be more favorable terms.
Key Highlights
- 1Abbott Ireland Financing DAC, a subsidiary of Abbott Laboratories, plans to issue senior unsecured notes.
- 2The offering is conducted under Regulation S, exempting it from U.S. Securities Act registration.
- 3Abbott Laboratories will unconditionally and irrevocably guarantee the notes.
- 4The notes are unsecured and unsubordinated.
- 5Proceeds will be used to redeem/repay a portion of Abbott's 2.900% Notes due 2021.
- 6Costs associated with the redemption, including premium and accrued interest, will also be covered.
- 7The offering is subject to market and other conditions.